astronomy

Lotte Bjerre Knudsen

Lotte Bjerre Knudsen is a astronomy topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Lotte Bjerre Knudsen rather than just read about it. In short: Lotte Bjerre Knudsen (born 10 March 1964) is a Danish scientist and university professor. She led the development of liraglutide and oversaw the development of semaglutide, two notable drugs approved for indications in the treatment of diabetes and obesity.

Key takeaways

Lotte Bjerre Knudsen belongs to astronomy; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Lotte Bjerre Knudsen to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Lotte Bjerre Knudsen from memory before moving on to harder problems.

Reference excerpt

Lotte Bjerre Knudsen (born 10 March 1964) is a Danish scientist and university professor. She led the development of liraglutide and oversaw the development of semaglutide, two notable drugs approved for indications in the treatment of diabetes and obesity.

Early life and education Knudsen originally studied chemical engineering at the Technical University of Denmark, and obtained a doctorate in scientific medicine (DMSc) from the University of Copenhagen in 2014.

Career Knudsen began work as a scientist at the pharmaceutical company Novo Nordisk in Denmark in 1989. As of December 2015, she was being referred to as Scientific Vice President for Global Research at Novo-Nordisk. She served as an adjunct faculty member at Aarhus University from 2015–2020, as a professor in translational medicine. Knudsen has been employed as a Chief Scientific Advisor in Research and Early Development at Novo Nordisk.

Contributions While still a student, Knudsen worked at Novo Nordisk, initially working on laundry detergent enzymes. Alongside fellow student Shamkant Patkar, she discovered an enzyme capable of removing microscopic strands of cotton that pill up on clothing from repeated wear. After this project, Knudsen joined full-time as part of a research group at Novo Nordisk that aimed to identify new treatments for diabetes, by developing small molecule drugs targeting specific metabolic pathways. One project revolved around glucagon-like peptide-1 (GLP-1), a hormone that stimulates the production of insulin but has a short half-life of minutes in the body. GLP-1 had been previously identified by researchers such as Jens Juul Holst in Denmark, who joined Novo Nordisk as a consultant, and Joel Habener, Daniel J. Drucker, and Svetlana Mojsov at Massachusetts General Hospital. Knudsen's team screened numerous chemical compounds to identify whether they could bind to the GLP-1 receptor sufficiently to stimulate insulin secretion. Eventually, they developed a new compound called liraglutide, which is an agonist for the GLP-1 receptor. It is a chemical analogue of GLP-1, with a fatty acid and spacer attached. These modifications increased its ability to dissolve in water and bind to albumin, which increase its bioavailability—its lifetime in the bloodstream, and so the duration of its action in the body. Liraglutide was approved as a treatment for diabetes under the brand name Victoza in the United States in 2010. Knudsen’s team, specifically Jesper Lau and Thomas Kruse, then worked on what became semaglutide, which had greater stability and affinity to albumin, lengthening its duration of action further to a once-weekly drug. Semaglutide was approved in the United States under the brand name Ozempic as a treatment for type 2 diabetes in 2017, and under the brand name Wegovy, as a first injectable (at 2.4 mg once weekly), for chronic weight management in June 2021. In January 2025, the FDA approved a pill form of Wegovy with doses ranging from 1.5 mg to 25 mg.

Impact

Martin Müller and Alexander Preker, writing for Der Spiegel in January 2024, have referred to Knudsen discovery in inventing the semaglutide weight-loss injections as "revolutionary", with the "drug Wegovy... [having] changed the world," and having made Novo Nordisk "Europe's most valuable company, [more valuable] than Daimler, Bayer, Lufthansa and BMW combined". In the initial clinical trials for Wegovy, diabetics lost more than 10% of their weight and in trials for weight loss, patients lost an average of 12.4% of their weight. Additional patient benefits included reduction of cardiovascular events by 25%, and benefits to patients with heart and kidney failure. The GLP receptor agonists have dramatically reformed treatment outcomes for obesity and diabetes "with profound implications for maintaining human health".

Honors and recognition Knudsen received the 2023 Paul Langerhans Medal by the German Diabetes Society for her work developing liraglutide. In October 2023, she received the STAT Biomedical Innovation award, and in 2024, she received the Mani L. Bhaumik Breakthrough of the Year Award. In 2024 she received the Lasker Award in clinical research. In 2024, Knudsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. In 2025, Knudsen received the 2025 Breakthrough Prize in Life Sciences.

Further reading Underwood, C.R.; Garibay, P.; Knudsen, L.B.; Peters, G.H.; Rudolph, R. & Reedtz-Runge, S. (January 2010). "Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor". J. Biol. Chem. 285 (1): 723–730. doi:10.1074/jbc.M109.033829. PMC 2804221. PMID 19861722.{{cite journal}}: CS1 maint: multiple names: authors list (link) Nielsen, Malene Løvig (18 December 2015). "Pharmaceutical Researcher is New Honorary Professor at Health". AU.dk. Retrieved 13 May 2024. Lotte Bjerre Knudsen from Novo Nordisk is a new honorary professor at Health, Aarhus University. She is the person behind the discovery of liraglutide, a new class of drugs for Novo Nordisk that are used in the treatment of type 2 diabetes and obesity.

References

External links The German Wikipedia page for Lotte Bjerre Knudsen. An unofficial source listing the publications of Knudsen. A formal source of patents issued to Knudsen. The 2022 Danish TV mini-series, "The Story of GLP-1", focused on the work of Knudsen.

Worked examples

Example 1 — a first encounter with Lotte Bjerre Knudsen

Start with the simplest possible case. Write down what Lotte Bjerre Knudsen claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In astronomy, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Lotte Bjerre Knudsen before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Lotte Bjerre Knudsen ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Lotte Bjerre Knudsen

In research: Lotte Bjerre Knudsen appears in astronomy research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Lotte Bjerre Knudsen in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Lotte Bjerre Knudsen is common in secondary-school and first-year university syllabi. It links to neighbouring topics 1964 births, Academic staff of Aarhus University, Biotechnologists, so understanding it makes those chapters shorter.
In everyday life: Look for Lotte Bjerre Knudsen outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Lotte Bjerre Knudsen” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Lotte Bjerre Knudsen in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Lotte Bjerre Knudsen means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Lotte Bjerre Knudsen out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Lotte Bjerre Knudsen in simple terms?

Why does Lotte Bjerre Knudsen matter?

Because it connects several astronomy ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Lotte Bjerre Knudsen?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Lotte Bjerre Knudsen.